ENA Respiratory begins Part B dosing in INNA-051 Phase IIa community study

PUBT · 2d ago
ENA Respiratory begins Part B dosing in INNA-051 Phase IIa community study
  • Brandon Capital Partners portfolio company ENA Respiratory began dosing Part B participants in its Phase IIa POSITS study of INNA-051.
  • Trial targets prevention of symptomatic viral respiratory infections using once-weekly dry powder nasal spray designed to boost nasal host defenses.
  • Part B plans up to 900 participants across five US sites during the North American respiratory virus season, with three months of dosing.
  • Part A enrolled 200 participants, completed in May, with no safety concerns reported following four weeks of weekly dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brandon Capital Partners Pty Ltd published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.